ECG Cases

NOVEMBER 6, 2018

This Best Case Ever elucidates the practical challenges of working up pregnant patients in the ED with a suspicion of pulmonary embolism. Since this recording, the first ever multi-center prospective outcome study looking at the pulmonary embolism workup in pregnancy was published in the Annals of Internal Medicine.

Embolism 52

Embolism Pulmonary Outcomes Ultrasound 52

Frontiers in Cardiovascular Medicine

JUNE 5, 2024

After preoperative evaluation, coil embolization was successfully performed to treat the pseudoaneurysm, resulting in a satisfactory outcome at the 1-year follow-up.ConclusionCoil embolization serves as an effective treatment option for ascending aortic pseudoaneurysm in BD when open surgical repair and stent graft placement are unsuitable.

Embolism 52

Embolism Aortic Thrombosis Stents 52

Frontiers in Cardiovascular Medicine

JANUARY 7, 2024

However, conventional surgical and transcatheter arterial embolization treatments are less effective. In the present case, a 76-year-old hypertensive woman was admitted with dizziness and diagnosed with an unruptured bronchial artery aneurysm, which was treated by transcatheter arterial embolization and aortic stent-graft.

Embolism 59

Embolism Aneurysm Stents Stent 59

DAIC

MARCH 14, 2025

Some of the late-breaking topics that will be covered include transcatheter aortic valve replacement (TAVR), peripheral artery disease (PAD), and pulmonary embolism (PE): Impact of Age on Procedural Timing for Asymptomatic Severe Aortic Stenosis: Results from the Early TAVR Trial The PERFORMANCE II Trial: A Prospective Multicenter Single Arm Investigation (..)

TAVR 52

TAVR Aortic valve Peripheral Arterial Disease Embolism 52

Frontiers in Cardiovascular Medicine

MARCH 27, 2024

In this case report, we demonstrated that thrombus aspiration and in situ thrombolysis through the Guidezilla GEC are applicable to patients with PE in whom systemic thrombolysis is contraindicated, resulting in successful reperfusion and positive clinical outcomes.

Thrombolysis 64

Thrombolysis Embolism Pulmonary Anatomy 64

Frontiers in Cardiovascular Medicine

DECEMBER 20, 2023

Massive pulmonary embolism (MPE) carries significant 30-day mortality and is characterized by acute right ventricular failure, hypotension, and hypoxia, leading to cardiovascular collapse and cardiac arrest. Considerable heterogeneity in studies is a significant weakness of the available literature.

Embolism 56

Embolism Pulmonary Cardiac Arrest Hemorrhage 56

HCPLive

SEPTEMBER 1, 2024

Asundexian failed to prove noninferiority to apixaban for its primary efficacy outcome in the phase 3 OCEANIC-AF trial.

Embolism 69

Embolism Stroke Strokes Outcomes 69

American College of Cardiology

APRIL 10, 2025

Patients undergoing atrial fibrillation (AFib) ablation who were not properly anticoagulated and did not undergo preprocedural transesophageal echocardiogram (TEE) were significantly more likely to suffer from transient ischemic attack (TIA) or pulmonary embolism (PE).

Echocardiogram 58

Echocardiogram Ablation Atrial Fibrillation AFIB 58

Circulation: Cardiovascular Interventions

JANUARY 20, 2025

BACKGROUND:The aim of this study was to examine the impact of early versus delayed catheter-based therapies (CBTs) on clinical outcomes in patients with acute intermediate-risk pulmonary embolism (PE).METHODS:This Secondary outcomes included a composite of 30-day mortality, resuscitated cardiac arrest, and hemodynamic instability.

Embolism 40

Embolism Pulmonary Outcomes Cardiac Arrest 40

Frontiers in Cardiovascular Medicine

MARCH 27, 2024

Common embolism sites include the brain, spleen, kidneys, lungs, and intestines. Additionally, acute heart failure (AHF) can occur in up to 40% of cases, and its presence can impact the clinical outcomes of patients with IE. Cardiogenic shock (CGS) is often more likely to occur after AHF has taken place.

Cardiogenic Shock 64

Cardiogenic Shock Embolism Heart Failure Thrombosis 64

Journal of the American Heart Association

MARCH 21, 2025

BackgroundWe aimed to reevaluate randomized controlled trial data on outcomes of cerebral embolic protection device use during transcatheter aortic valve implantation. Primary outcomes included all stroke, disabling stroke, and allcause mortality.

Aortic valve 40

Aortic valve Embolism Aortic Stroke 40

Frontiers in Cardiovascular Medicine

JULY 1, 2024

Notably, acute massive pulmonary embolism (PE) with bilateral atrial thrombosis is an exceptional occurrence in CAPS. Acute pulmonary embolism (PE) is a common cardiovascular disease that progresses rapidly and has a high mortality rate. It primarily affects small vessels, seldom impacting large vessels.

Thrombosis 52

Thrombosis Embolism Pulmonary Laboratory 52

Frontiers in Cardiovascular Medicine

APRIL 10, 2025

The complexity of the condition of women with SjD and the incidence of complications substantially increase during pregnancy, which undoubtedly has consequences on both maternal health and neonatal outcomes. Pulmonary embolism (PE) is associated with increased perinatal mortality.

Embolism 40

Embolism Pulmonary Outcomes 40

Stroke Journal

FEBRUARY 1, 2024

Introduction:Middle meningeal artery embolization for chronic subdural hematomas is a promising treatment either as an adjuvant to surgical evacuation of the hematoma or as a primary treatment modality. A total of 67 patients (42%) were treated with particles and 93(58%) with liquid embolic agents. mm, p<0.59).Conclusions:The

Embolism 40

Embolism Stroke Strokes Outcomes 40

Heart BMJ

MAY 10, 2024

Objectives The use of cerebral embolic protection (CEP) during transcatheter aortic valve implantation (TAVI) has been studied in several randomised trials. The primary outcome was the risk of disabling stroke. The minimal clinically important difference was determined at 1.1% ARD, per expert consensus (NNT 91).

Aortic valve 52

Aortic valve Embolism Aortic Stroke 52

Stroke Journal

JANUARY 30, 2025

Middle meningeal artery (MMA) embolization is being utilized more frequently as adjunctive and primary treatment. Here, we present the outcomes of this technique with different embolic agents in our patient population.IRB approval was obtained for this study. Vulnerable populations were excluded. Mean age was 73 years.

Embolism 40

Embolism Stroke Strokes Outcomes 40

Frontiers in Cardiovascular Medicine

JULY 24, 2024

Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a severe and complex condition that evolves from unresolved pulmonary embolism, leading to fibrotic obstruction of pulmonary arteries, pulmonary hypertension, and potential right heart failure.

Pulmonary 98

Pulmonary Hypertension Angioplasty Pharmacology 98

JAMA Cardiology

NOVEMBER 21, 2023

This cohort study assesses outcomes in patients with pulmonary embolism using high-sensitivity vs conventional troponin I.

Embolism 40

Embolism Pulmonary Outcomes 40

CardiacWire

JANUARY 24, 2025

Despite these excellent bleeding results, AZALEA-TIMI 71s stroke outcomes were not strong enough to sway researchers one way or another due to the studys early termination and small sample size (28 patients had a stroke or systemic embolism). per 100 person-years vs. 0.83).

Stroke 59

Stroke Strokes AFIB Thrombosis 59

DAIC

JANUARY 30, 2025

a powerful and advanced mechanical thrombectomy system for the removal of venous thrombus and the treatment of pulmonary embolism (PE), effectively completing Penumbras VTE platform. Penumbras continuous advancements provide a comprehensive portfolio for physicians to treat a wider range of patients and improve patient outcomes.

Technology 52

Technology Anatomy Embolism Innovation 52

Stroke Journal

JANUARY 30, 2025

Disambiguating embolism etiology is important to improve treatment efficacy and reduce recurrent events. Additionally, the embolus source-destination likelihood mapping provides detailed quantitative insights on the embolism etiology in these stroke patients. Stroke, Volume 56, Issue Suppl_1 , Page ATP388-ATP388, February 1, 2025.

Embolism 40

Embolism Stroke Strokes Outcomes 40

Stroke Journal

FEBRUARY 1, 2024

The purpose of this study was to compare the outcomes of EVT for ICAD with those of cardiogenic cerebral embolism (CE) based on real-world data from a multicenter, prospective registry study (K-NET registry) involving 40 centers in Japan.Methods:The K-NET study enrolled 3187 EVTs in 2018-2021, of which 358 (11%) were ICAD and 1870 (59%) were CE.

Embolism 40

Embolism Outcomes Angioplasty Hemorrhage 40

Journal of the American Heart Association

JANUARY 19, 2024

BackgroundCerebral embolic protection devices (CEPD) capture embolic material in an attempt to reduce ischemic brain injury during transcatheter aortic valve replacement. Primary clinical outcome was all‐cause stroke. Secondary clinical outcomes were disabling stroke and all‐cause mortality.

Aortic valve 40

Aortic valve Embolism Aortic Stroke 40

The American Journal of Cardiology

OCTOBER 29, 2024

Publication date: Available online 28 October 2024 Source: The American Journal of Cardiology Author(s): Aryan Mehta, Mridul Bansal, Siddhant Passey, Saurabh Joshi, Carlos L Alviar, Jason N Katz, J Dawn Abbott, Saraschandra Vallabhajosyula

Embolism 40

Embolism Pulmonary Outcomes 40

The American Journal of Cardiology

JANUARY 1, 2025

Publication date: Available online 31 December 2024 Source: The American Journal of Cardiology Author(s): Aryan Mehta, Mridul Bansal, Abhishek Singh, Ritika Kompella, Anindita Chanda, Chirag Mehta, Christopher J Mullin, J Dawn Abbott, Saraschandra Vallabhajosyula

Embolism 40

Embolism Pulmonary Hospital Outcomes 40

Stroke Journal

JANUARY 30, 2025

Background:The use of oral anticoagulation (OAC) for stroke prevention in embolic stroke of undetermined source (ESUS) is hypothesized to be beneficial over conventional antiplatelet use. The primary outcome was stroke recurrence, and the safety outcome was major bleeding. A random-effects model was used for the analyses.

Embolism 40

Embolism Stroke Strokes Cardiomyopathy 40

Dr. S. Venkatesan MD

OCTOBER 15, 2024

A new Intelligent thrombo-suction catheter system , is being introduced for treatment of acute pulmonary embolism.This device regulates the force with which thrombus is sucked , with less injury and bleeding and better outcomes. Human studies & Evidence The experience from this device was presented in ESC 2024 London.

Technology 52

Technology Pulmonary Embolism Innovation 52

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

The inflow aneurysms were accessed and embolized with coils using a second microcatheter prior to AVM embolization. Extensive but partial filling of the AVM was noted anteriorly but full embolization of the posterior aspect of the nidus was not achieved. Onyx‐18 was then injected into the main AVM pedicle under a blank roadmap.

Aneurysm 40

Aneurysm Embolism Hemorrhage Hypertension 40

Stroke Journal

APRIL 2, 2025

Clinical outcomes were measured at 1, 6, and 12 months after discharge. Radiological outcomes were measured at birth, discharge, and 3 to 9 months after discharge. FS was correlated with clinical outcomes using logistic regression, with the predicted risk of the outcome per unit FS measurement calculated through marginal analysis.

Outcomes 45

Outcomes Pediatrics Embolism Stroke 45

Stroke Journal

FEBRUARY 1, 2024

Previous studies have noted that ICAD-related LVOs, compared to embolic occlusions, have longer procedural times and lower successful reperfusion rates. However, clinical outcomes remain similar. Patient outcomes at 3 months were assessed using modified Rankin Scale (mRS) scores, defining devastating outcomes as mRS 5-6.

Outcomes 40

Outcomes Embolism Atrial Fibrillation Thrombolysis 40

DAIC

FEBRUARY 12, 2024

This critical information empowers physicians to select the most suitable endovascular therapeutic approach, thereby mitigating complications, avoiding embolization, and enhancing long-term treatment outcomes.

Peripheral Arterial Disease 105

Peripheral Arterial Disease Technology Embolism Hospital 105

Frontiers in Cardiovascular Medicine

DECEMBER 3, 2024

BackgroundThrombocytopenia is often associated with adverse outcomes in patients with atrial fibrillation. Compared to no thrombocytopenia, atrial fibrillation patients combined with thrombocytopenia have a significant risk reduction of ischemic stroke/systemic embolism [OR: 0.79, 95% CI: (0.69, 0.91); P < 0.01].

Atrial Fibrillation 40

Atrial Fibrillation Embolism Outcomes Stroke 40

Journal of Cardiovascular Electrophysiology

DECEMBER 23, 2024

This has been associated with poor clinical outcomes. We aim to investigate the impact of anemia on clinical outcomes in patients with AF on oral anticoagulation. However, the impact of anemia did not significantly affect the risk of stroke, transient ischemic stroke (TIA), or systemic embolism (HR: 1.07

Atrial Fibrillation 40

Atrial Fibrillation Outcomes Embolism Hemorrhage 40

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

We present a single‐center experience describing the characteristics and outcomes of treated and untreated IIAs.MethodsThis is a single‐center retrospective observational study of patients admitted with IE who developed IIAs and were admitted at our institute from 2016 to 2022. underwent n‐BCA embolization, 14.2% 9); (P=0.002).

Aneurysm 40

Aneurysm Embolism Outcomes Hospital 40

American College of Cardiology

APRIL 16, 2024

What are the in-hospital and readmission outcomes in patients with intermediate-risk or high-risk pulmonary embolism (PE) treated with versus without catheter-based therapies (CBTs) in a large retrospective registry?

Embolism 56

Embolism Pulmonary Hospital Outcomes 56

Open Heart

MAY 11, 2023

The aim of our study was to investigate factors associated with patient refusal of anticoagulation and the clinical outcomes in these patients. Further research is required to understand the patient profile and mortality outcome of patients who refuse anticoagulation.

Outcomes 52

Outcomes Blood Pressure Atrial Fibrillation Embolism 52

Journal of the American Heart Association

FEBRUARY 14, 2025

The primary effectiveness outcomes were ischemic stroke or systemic embolism, and bleeding for safety. In the matched cohort, DOAC use (versus warfarin) was associated with a lower rate of ischemic stroke or systemic embolism (HR, 0.70 [95% CI, 0.610.81]) and bleeding (HR, 0.72 [95% CI, 0.650.80]).

Atrial Fibrillation 51

Atrial Fibrillation Heart Disease Embolism Stroke 51